CN102164579A - 苯达莫司汀的液体配制品 - Google Patents
苯达莫司汀的液体配制品 Download PDFInfo
- Publication number
- CN102164579A CN102164579A CN2009801379775A CN200980137977A CN102164579A CN 102164579 A CN102164579 A CN 102164579A CN 2009801379775 A CN2009801379775 A CN 2009801379775A CN 200980137977 A CN200980137977 A CN 200980137977A CN 102164579 A CN102164579 A CN 102164579A
- Authority
- CN
- China
- Prior art keywords
- preparation
- bendamustine
- pharmaceutically acceptable
- proton solvent
- aqueous polar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002707 bendamustine Drugs 0.000 title claims abstract description 97
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 239000012669 liquid formulation Substances 0.000 title abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims description 160
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 64
- 239000002904 solvent Substances 0.000 claims description 46
- 238000003860 storage Methods 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- 238000004458 analytical method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- -1 dimethyl sulfoxine Chemical compound 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- JKJWYKGYGWOAHT-UHFFFAOYSA-N bis(prop-2-enyl) carbonate Chemical compound C=CCOC(=O)OCC=C JKJWYKGYGWOAHT-UHFFFAOYSA-N 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 229940034982 antineoplastic agent Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 5
- CFQPVBJOKYSPKG-UHFFFAOYSA-N 1,3-dimethylimidazol-2-one Chemical compound CN1C=CN(C)C1=O CFQPVBJOKYSPKG-UHFFFAOYSA-N 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 150000003140 primary amides Chemical class 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 4
- 230000002045 lasting effect Effects 0.000 claims 4
- 150000001298 alcohols Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000008354 sodium chloride injection Substances 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 1
- 150000002334 glycols Chemical class 0.000 claims 1
- 239000003880 polar aprotic solvent Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 17
- 238000010268 HPLC based assay Methods 0.000 description 11
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229940066958 treanda Drugs 0.000 description 7
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000010 aprotic solvent Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- GPYWLSZJZNELNN-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]-4-hydroxybutanoic acid Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(C(O)CCC(O)=O)=NC2=C1 GPYWLSZJZNELNN-UHFFFAOYSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 239000004594 Masterbatch (MB) Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
本发明公开了苯达莫司汀和它的药学上可接受的盐以及极性非质子溶剂的稳定的液体配制品。
Description
技术领域
本发明涉及苯达莫司汀以及它的药用盐的液体配制品。
发明背景
苯达莫司汀,4-{5-[双(2-氯乙基)氨基]-1-甲基-2-苯并咪唑基}丁酸,是一个具有苯并咪唑环的不规则结构,该结构包括一个活性氮芥。苯达莫司汀最初于1963年在德意志民主共和国合成,并且从1971到1992年在该处以商品名Cytostasan可得。自那时以后,它已经以商品名Ribomustin在德国市场化。它现在在美国以商品名Treanda(Cephalon,Inc.,Frazer,PA)可供使用。它已经被广泛用于治疗慢性淋巴细胞白血病、何杰金氏病、非何杰金氏淋巴瘤、多发性骨髓瘤以及乳癌
像其他氮芥一样,苯达莫司汀在水溶液中水解,其中主要降解物是伯醇HP1(参见美国申请No.11/330,868,它的全文结合在此):
鉴于苯达莫司汀在水溶液中的不稳定性,它现在主要作为用于注射的冻干粉末而提供。就在它的输注前,医学工作者将该粉末用无菌水复水用于注射。复水应该产生一种透明的、无色到浅黄色的溶液并且该粉末应该在约5分钟内完全溶解。如果观察到微粒状物质,则该复水产品不应被使用并应该被丢弃掉。然后在复水30分钟以内将该复水产品转移到0.9%的氯化钠注射输液袋中。这一混合物应该是透明的、并且无色到微黄的溶液。如果该混合物包括微粒状物质或是变色的,则它应该被丢弃并且制备新鲜的样品。
苯达莫司汀的冻干粉末的复水是费时且麻烦的。此外,处于商业规模的固体的冷冻干燥要求专门的设备并且招致显著的费用。这样,对于不要求冷冻干燥和/或复水的苯达莫司汀的配制品存在需要。
已经报告了(GDR专利159289)在惰性气体的气氛下制备苯达莫司汀盐酸盐在无水丙二醇中的溶液。报告了使用薄层色谱法(用丁醇/乙酸/水(4∶1∶5)洗脱)对这些溶液的分析以及用德拉根道夫试剂和紫外线(360nm)的检测并没有表明任何分解。然而奇怪的是丙二醇配制品的商业发展迄今还没有被报道。因此,对于苯达莫司汀的改进的液体配制品仍然存在需要。
发明概述
本发明针对液体药物配制品,包括苯达莫司汀或它的一种药学上可接受的盐或药物前体,以及一种极性非质子溶剂。某些优选的实施方案包括液体药物配制品,该液体药物配制品包括苯达莫司汀或它的一种药学上可接受的盐或药物前体、一种极性非质子溶剂以及一种非水极性质子溶剂。还描述了制造和使用本发明的配制品的多种方法,以及使用提出权利要求的配制品来治疗癌症的方法。
附图简要说明
图1是苯达莫司汀在25℃下在不同溶剂中的稳定性分析的曲线图。
图2是苯达莫司汀在5℃下在不同溶剂中的稳定性分析的曲线图。
图3是在5℃和在25℃下、在99%丙二醇中苯达莫司汀纯度随时间变化的曲线图。
图4显示了雄性食蟹猴(N=4)内苯达莫司汀的平均+标准差浓度-对比-时间变化的曲线,这些雄性食蟹猴被给予了在3种不同配制品中的3mg/kg的弹丸静脉内剂量的苯达莫司汀盐酸盐。
发明详细说明
已经发现了苯达莫司汀的稳定的液体配制品并且在此进行了报告。
已经完成了生产商业上可行的丙二醇制剂的实验。不幸的是,在GDR专利159289中描述的结果是不可再现的。苯达莫司汀在99%的丙二醇中的溶液在经过与商业储存相等的一段时间后降解为非苯达莫司汀的产物。该杂质中的两种被鉴定为苯达莫司汀的丙二醇酯。这样,苯达莫司汀的100%丙二醇商业配制品对于药用目的来说是不可行的。
已经确定苯达莫司汀以及它的药学上可接受的盐(特别是盐酸盐)的药学上可接受的液体配制品可以通过使苯达莫司汀或它的药学上可接受的盐与一种极性非质子溶剂或多种极性非质子溶剂的混合物相结合来制备。极性非质子溶剂在本领域中是已知的并且包括,例如1-甲基-2-吡咯烷酮、1,3-二甲基-2-咪唑啉酮、二甲基乙酰胺、二甲亚砜、丙酮、四氢呋喃、1,4-二氧六环、乙腈、二甲基甲酰胺、碳酸丙烯酯。也见于例如Florence Mottu,et al.Organic solvents for pharmaceutical parenterals and embolic liquids:A review of toxicity data,PDA J.Pharma.Sci.& Tech.vol 54,no.6,456-469(Nov.-Dec.2000).特别优选的极性非质子溶剂包括二甲基乙酰胺、二甲亚砜和它们的混合物。
不希望受任何特定理论所束缚,人们认为对于苯达莫司汀,极性非质子溶剂是足够非亲核性的,这样使得经过典型的商业储存条件的过程不会形成极性非质子溶剂-苯达莫司汀加合物。典型的商业储存条件包括多个时间段,例如约30天、约90天、约180天,以及约365天(约1个月、约3个月、约6个月,以及约1年)。典型的商业储存条件还包括约23℃的温度(周围室温)以及低于周围室温的冷藏温度,例如约5℃。优选地,本发明的液体配制品在冷藏温度下储存。
还已经发现,苯达莫司汀的稳定配制品可以通过将一种极性非质子溶剂或多种极性非质子溶剂的混合物与一种非水极性质子溶剂或多种非水极性质子溶剂的混合物进行混合而获得。药学上可接受的非水极性质子溶剂是在本领域中已知的并且包括烷基醇,例如乙醇、乙二醇、丙二醇、丁二醇、丙三醇、聚山梨醇酯(例如TWEEN 20、TWEEN40和TWEEN 80),以及环糊精(例如羟丙基-β-环糊精)、聚亚烷基二醇(例如聚乙二醇、聚丙二醇以及聚丁二醇),以及伯酰胺(例如烟酰胺)。
此类配制品将典型地包括按配制品的体积计90%或更少的非水极性质子溶剂。在其他优选实施方案中,配制品将包括按配制品的体积计在约20%和约85%之间的非水极性质子溶剂。在仍其他优选实施方案中,配制品将包括按配制品的体积计在约30%和约70%之间的非水极性质子溶剂。在最优选的实施方案中,配制品将包括按配制品的体积计约80%、约67%或约34%的非水极性质子溶剂。
可替代地,本发明的配制品将包括10摩尔/升或更少的非水极性质子溶剂。优选地,本发明的配制品将包括在约4摩尔/升和约9.5摩尔/升之间的非水极性质子溶剂。在某些实施方案中,配制品将包括约9.1摩尔/升的非水极性质子溶剂。在其他实施方案中,配制品将包括约4.6摩尔/升的非水极性质子溶剂。
虽然不希望被限制在任何特定理论,但是人们认为非水极性质子溶剂具有足够的亲核性来形成潜在的不希望的极性质子溶剂-苯达莫司汀加合物,如果该极性质子溶剂保持在本发明的范围以内,则此类加合物在典型的商业储存的过程中将不会形成。
在典型的商业储存时间段的过程中,本发明的液体配制品是稳定的。如在此处使用的,“稳定”被定义为在典型的商业储存条件下,不超过约10%的苯达莫司汀的损失。优选地,在典型的商业储存条件下,本发明的配制品将具有不超过约10%的苯达莫司汀的损失,更优选地,不超过约5%的苯达莫司汀的损失。
当暴露至某些亲核试剂使,例如水和亚烷基二醇(例如丙二醇)中时,苯达莫司汀转化为多种非苯达莫司汀产物(即,“降解物”)。苯达莫司汀暴露在水中时可以产生不希望的“HP1”。
苯达莫司汀随时间变化可以转化成的另一种不希望的化合物是“BM1二聚物”。
苯达莫司汀随时间变化可以转化成的仍另一种化合物是“DCE”。
当暴露至一种亚烷基二醇(例如丙二醇)时,可以形成苯达莫司汀的酯,例如PG-1和PG-2。
在本发明的优选实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,对本发明的配制品的分析将呈现1.50%或更少的DCE。更优选地,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现1.0%或更少的DCE。甚至更优选地,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现0.5%或更少的DCE。最优选地,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现约0.1%或更少的DCE。
在本发明的其他实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,对配制品的分析将呈现约0.4%或更少的HP1。优选地,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现约0.10%或更少的HP1。
在本发明的某些其他实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,对配制品的分析将呈现约0.70%或更少的BM1二聚物。优选地,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现约0.30%或更少的二聚物。在最优选的实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,这些配制品将呈现约0.10%或更少的BM1二聚物。
在包括亚烷基二醇作为非水极性质子溶剂的那些本发明的实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,对那些配制品的分析将呈现1.5%或更少的苯达莫司汀的亚烷基二醇酯。例如,在那些包括丙二醇的实施方案中,在约5℃下约1年(约365天)后,如通过HPLC分析测定的,对那些配制品的分析将呈现1.5%或更少的丙二醇酯PG-1和PG-2。
本发明的液体配制品的分析可以使用本领域中已知的技术(包括例如HPLC、气相色谱法以及NMR)来完成。在暴露于典型的商业储存条件后,对本发明的配制品的分析将显示该配制品含有不少于暴露于储存条件之前所存在的苯达莫司汀的量的约90%。优选地,分析将显示该配制品含有不少于暴露于储存条件之前所存在的苯达莫司汀的量的约95%。
在本发明的优选实施方案中,对本发明的配制品的分析将显示该配制品含有不少于暴露于储存条件之前所存在的苯达莫司汀的量的约90%,这些储存条件包括温度为约5℃并且时间段为约30天(约1个月)到约365天(约一年)。优选地,对本发明的配制品的分析将显示该配制品含有不少于暴露于储存条件之前所存在的苯达莫司汀的量的约90%,这些储存条件包括温度为约5℃并且时间段为约30天(约1个月)、约90天(约三个月)以及约180天(约6个月)。优选地,分析将显示该配制品含有不少于暴露于储存条件之前存在的苯达莫司汀的量的约95%,这些储存条件包括温度为约5℃并且时间段为约30天(约1个月)到约365天(约一年)。更优选地,分析将显示该配制品含有不少于暴露于储存条件之前多存在的苯达莫司汀的量的约95%,这些储存条件包括温度为约5℃并且时间段为约30天(约1个月),约90天(约三个月)以及约180天(约6个月)。
本发明的配制品可以包括药学上有用的浓度的苯达莫司汀,或它的一种药学上可接受的盐。有用的浓度包括的浓度范围是从约5mg/mL到约200mg/mL。优选地,苯达莫司汀或它的一种药学上可接受的盐的浓度范围是从约5mg/mL到约120mg/mL。优选的浓度包括约5mg/mL、约10mg/mL、约20mg/mL、约30mg/mL、约40mg/mL、约50mg/mL、约60mg/mL、约100mg/mL以及约200mg/mL的苯达莫司汀或它的一种药学上可接受的盐。大于200mg/mL的苯达莫司汀或它的药学上可接受的盐,例如大于300mg/mL,也在本发明的范围内,苯达莫司汀或它的药学上可接受的盐的饱和溶液也是如此。
如在此处使用的,术语“约”被定义为±10%,优选地±5%。
除了包括一种极性非质子溶剂或多种极性非质子溶剂的混合物,以及任选地,一种非水极性质子溶剂或多种溶剂的混合物,本发明的配制品可以进一步包括其他药学上可接受的赋形剂。药学上可接受的赋形剂是本领域内已知的并且包括,例如抗氧化剂(例如生育酚(维生素E)、抗坏血酸、对羟基苯甲酸甲酯、丁羟基茴香醚(BHA)、丁羟基甲苯(BHT)以及没食子酸丙酯),表面活性剂(例如聚山梨醇酯(TWEEN 20、TWEEN 40、TWEEN 80)),类脂(例如二肉豆蔻磷脂酰胆碱(DMPC)、二肉豆蔻磷脂酰甘油(DMPG)、二硬脂酰磷脂酰甘油(DSPG)),填充剂(例如甘露醇),有机酸(例如柠檬酸、乳酸、苯甲酸),亲水性聚合物(例如聚乙二醇(PEG 300、PEG 400)),络合剂(例如烟酰胺、烟酸、肌酸、环糊精)以及防腐剂(例如苯甲醇)。
同样在本发明范围之内的是用一种本发明的药物配制品治疗疾病(例如像慢性淋巴细胞白血病、何杰金氏病、非何杰金氏淋巴瘤、多发性骨髓瘤、或乳癌)的多种方法。这些方法包括向患者给予一个治疗有效量的从一种本发明的药物配制品制备的一种制剂。在此所使用的术语“治疗有效量”是指所确定的、产生预期的生理效应所要求的并且与一种给定的药物相关联的量,如对于给定的给药途径根据已确定的药物代谢动力学方法和技术所测量的。适当的并且具体的治疗有效的量可以由作为本领域的普通技术人员的主治诊断医生通过使用常规的技术很容易进行确定。有效剂量将取决于多种因素而变化,这些因素包括疾病或病症的类型和进展程度、具体患者的总体健康状况、所选择的化合物的相对生物学疗效、活性试剂与适当的赋形剂的配制品、以及给药途径。
在此描述的这些苯达莫司汀的液体配制品旨在通过注射给药,例如它们可以皮下地、皮内地、静脉内地、肌内地、关节内地、滑膜内地、胸骨内地、鞘内地、损伤区内地、颅内地或经输注给药。在一个典型的制备过程中,可以将对于所要求的剂量所需要的体积的本发明的液体配制品无菌地抽出并且转移到用于注射的0.9%氯化钠(或其他药学上可接受的静脉内溶液)的一个输液袋中。在转移之后,将该输液袋的内含物充分混合。通过静脉内输注的给药典型地是经从约30分钟至约60分钟的时间段来提供的。之前描述的苯达莫司汀的冻干配制品在输注前要求在与多种可接受的静脉内溶液混合前将冻干的苯达莫司汀进行复水。
所设想到的是,本发明的这些药物配制品和制剂可以与一种或多种抗肿瘤药组合给予,其中该抗肿瘤药是在给予本发明的配制品或制剂之前、与其同时、或之后给予。药学上可接受的抗肿瘤药在本领域中是已知的。优选的抗肿瘤药是披露于2006年1月12日提交的共同未决的美国申请号11/330,868(将其通过引用以全文结合在此)中的那些。
实例
在极性非质子溶剂中苯达莫司汀盐酸盐的溶解度和稳定性
对于多种溶剂确定了平衡溶解度,这些溶剂包括1-甲基-2-吡咯烷酮(NMP)、1,3-二甲基-2-咪唑啉酮(DMI)、二甲基乙酰胺(DMA)、二甲亚砜(DMSO)、丙酮、四氢呋喃(THF)、二甲基甲酰胺(DMF)以及碳酸丙烯酯(PC)。还对于两种溶液(在DMA中的25mg/mL烟酰胺以及66%的DMA/34%的丙二醇(PG))测定了苯达莫司汀盐酸盐的溶解度。对于每种溶剂或溶液将苯达莫司汀盐酸盐的饱和溶液制成一式三份并且在一个实验室振荡器上通过在室温下持续3天的温和混合以及低剪切进行混合。将每种悬浮液的一个样品放入一个微量离心管中,并且在一台Eppendorf微量离心机上以10,000rpm的速度旋转5分钟。将上清液移出并且放入一个干净的小瓶中。将每种溶液用样品溶剂(50%的NMP/50%的0.1%三氟乙酸在水中)稀释。使用一种针对苯达莫司汀盐酸盐的反相方法来测定由一种标准物计算出的每种样品的浓度。在制备稀释样品18小时以内进行分析。溶解度在以下表I中列出。每个值都是三个样品的平均值。
表I
样品* | %纯度 | 测定值(mg/mL) |
NMP | 99.1 | 104.0 |
DMI | 98.5 | 75.8 |
DMSO | 99.5 | 311.7 |
DMF | 99.6 | 71.8 |
66%DMA/34%PG | 99.5 | 110.1 |
DMA | 99.4 | 56.2 |
PC | 98.7 | 7.7 |
烟酰胺/DMA | 99.2 | 61.3 |
*丙酮和THF没有可测量的苯达莫司汀的溶解度。
将三个复制品合并并且充分混合,并且之后用移液管移进琥珀色HPLC小瓶中并且置于25℃和5℃的稳定性室内。所有样品都是透明并且无色的,除了DMI样品是透明并且黄色的。从约180天(约6个月)到约365天(约12个月,约1年),该25℃稳定性变得平稳。在5℃下,所有溶液都具有大于90%的纯度。对稳定性样品的分析可以从图1和图2的曲线图中看到。
表II
在5℃下储存约12个月后,苯达莫司汀盐酸盐的某些液体配制品的杂质曲线
ND=未检测到
用50%的NMP/50%的在水中的0.1%三氟乙酸作为流动溶剂,使用反相HPLC进行分析。
如图3中可出的,当在25℃下储存少于100天时,在99%的丙二醇中的苯达莫司汀(BM1)显著地降解。在5℃下储存约365天后,苯达莫司汀的纯度为约80%或更少。
在猴子体内的多种配制品的药物代谢动力学研究
4只禁食(18-23小时)、初次接受药物的雄性食蟹猴按顺序接受单次的由3种不同的配制品制备的苯达莫司汀盐酸盐的3-mg/kg弹丸静脉内剂量。本研究中评估的这些配制品包括:
1)TREANDA(苯达莫司汀盐酸盐和甘露醇的冻干混合物;25mg的(苯达莫司汀盐酸盐)小瓶;2)一种66%二甲基乙酰胺(DMA)/34%丙二醇(PG)(w/w)溶液(90mg(苯达莫司汀盐酸盐)/mL母液);以及3)一种100%DMA溶液(45mg(苯达莫司汀盐酸盐)/mL母液)。该苯达莫司汀盐酸盐的冻干粉末和母料溶液用0.9%盐水复水或稀释(适当时)以在剂量给予前给出3mg苯达莫司汀盐酸盐/mL的溶液。将这些制成的溶液经由一根隐静脉以1.0mL/kg的固定体积作为一次弹丸进行给药。存在分开这些连续剂量的至少一个7天的洗脱期。在给药的所有3个阶段中,直接在给药前以及在穿过给药后12小时的预选时间点经由一根大腿静脉收集用于苯达莫司汀和它的2种活性循环代谢物(γ-羟基苯达莫司汀(M3)和N-去甲基苯达莫司汀(M4))的药物代谢动力学曲线的血样。使用带有串联质谱检测(LC-MS/MS)的一种证实的高效液相色谱法按如下所述测定血浆样品中苯达莫司汀、M3和M4的浓度。通过使用乙腈进行蛋白质沉淀从血浆中提取苯达莫司汀以及M3和M4代谢物。在提取后,将该等分的样品用1%的甲酸酸化,并且作为一种内标物添加在羧酸链中具有添加的碳的苯达莫司汀。将这些样品蒸发至干燥并且将残余物用一种乙腈/水/甲酸/甲酸铵混合物进行复水。将样品注入一个带有LC/MS/MS检测的HPLC系统内,使用一种具有乙腈/水/甲酸/甲酸铵作为流动相的Phenomenex Synergi Max-RP柱。使用无房室法进行药物代谢动力学分析。
在向雄性食蟹猴单次弹丸静脉内给予苯达莫司汀盐酸盐后,苯达莫司汀的平均血浆浓度-对比-时间的曲线的形状在这3种配制品的每一个中都是类似的(参见图4)。在所有情况下,在给药后0.083小时(即在给药后第一取样时间)达到了观察到的最高的苯达莫司汀血浆水平,并且随后该化合物从血浆中的去除以一种两阶段的方式发生,其特征为一个初始的快速分布阶段以及一个在某种程度上更慢的药物消除的末期阶段。对于每种配制品,该末期阶段的调和平均值t1/2为近似0.6小时(参见表III)。
除了这些平均血浆浓度-对比-时间的曲线在形状上的相似性之外,这3种配制品还在苯达莫司汀的系统性暴露(即Cmax和AUC)方面相类似。具体地讲,对于TREANDA配制品,苯达莫司汀的Cmax和AUC0-∞的平均值分别为6037ng/mL和2314ng·hr/mL,对于66%DMA/34%PG的配制品分别为7380ng/mL和2854ng·hr/mL,并且对于100%DMA的配制品分别为6209ng/mL和2372ng·hr/mL。苯达莫司汀的血浆清除率(CL)和分布容积(Vz和Vss)在这3种配制品的每一种之间也是可比较的(参见表III)。在表III中,tmax、hr作为中值[范围]给出,t1/2、hr作为调和均值给出,λz、hr-1在消除阶段中是线的斜率,被用来计算半衰期,并且MRT0-∞是平均停留时间。
总而言之,在对猴子进行单次弹丸静脉内给药后,对于苯达莫司汀盐酸盐的2种液体配制品而言苯达莫司汀、M3和M4的药物代谢动力学曲线在质量上以及数量上与对于TREANDA配制品所获得的那些曲线相类似。
表III显示了给予在三种不同的配制品中的单次3mg/kg弹丸静脉内剂量的苯达莫司汀盐酸盐的雄性食蟹猴(N=4)体内苯达莫司汀的均值+/-标准差药物代谢动力学参数。
表III
配制品的使用中研究
以高剂量(360mg苯达莫司汀盐酸盐)制备在0.9%氯化钠溶液(500mL的袋)中的混合物,并且在室温下使用HPLC测定随时间变化的纯度,持续长达8小时,使用了一个Zorbax Bonus-RP柱,其中的梯度是从93%的在水中的0.1%三氟乙酸(流动相A)/7%的在乙腈中的0.1%三氟乙酸(流动相B)到10%的流动相A/90%的流动相B。
66%DMA/34%PG配制品具有的苯达莫司汀盐酸盐的浓度为90mg/g,所以将4mL注入500mL的盐水袋中,倒转10次并且在室温下取样,持续8小时。8小时后纯度为95.4%。这在用于Treanda给药的标签要求之内。本发明的这种配制品可以在室温下使用长达8小时。通过对比,复水的Treanda只能在室温下储存达3小时。
该100%DMA的配制品具有45mg/g的浓度,所以将8mL注入到500mL的盐水袋中,倒转10次,并在室温下取样,持续4小时。4小时后纯度为97.9%。本发明的这种配制品可以在室温下使用长达4小时。
在25℃下4小时后,对比性的Treanda混合物纯度为95.0%。
如本领域的普通技术人员将理解到的,鉴于以上传授内容,本发明的多种改变和变更是有可能的。因此应理解的是,在权利要求书的范围之内,本发明可以如在此所确切说明的之外,以其他方式来实施,并且本发明的范围旨在涵盖所有的此类变化。
Claims (62)
1.一种液体药物配制品,包括苯达莫司汀或它的一种药学上可接受的盐或药物前体,以及一种极性非质子溶剂。
2.如权利要求1所述的配制品,其中该极性非质子溶剂是1-甲基-2-吡咯烷酮、1,3-二甲基-2-咪唑啉酮、二甲基乙酰胺、二甲亚砜、丙酮、四氢呋喃、1,4-二氧六环、乙腈、二甲基甲酰胺、碳酸丙烯酯或它们的一种混合物。
3.如权利要求1所述的配制品,其中该极性非质子溶剂是二甲基乙酰胺、二甲亚砜或它们的一种混合物。
4.如权利要求1所述的配制品,进一步包括一种非水极性质子溶剂。
5.如权利要求4所述的配制品,其中该非水极性质子溶剂是一种醇、一种聚亚烷基二醇、一种酰胺或它们的一种混合物。
6.如权利要求4所述的配制品,其中该非水极性质子溶剂是一种醇。
7.如权利要求6所述的配制品,其中该醇是一种二醇。
8.如权利要求7所述的配制品,其中该二醇是乙二醇、丙二醇、丁二醇或它们的一种混合物。
9.如权利要求6所述的配制品,其中该醇是一种环糊精。
10.如权利要求9所述的配制品,其中该环糊精是羟丙基-β-环糊精。
11.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计90%或更少的非水极性质子溶剂。
12.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计约20%到约85%的非水极性质子溶剂。
13.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计约30%到约70%的非水极性质子溶剂。
14.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计约80%的非水极性质子溶剂。
15.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计约67%的非水极性质子溶剂。
16.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计约34%的非水极性质子溶剂。
17.权利要求4所述的配制品,其中该极性非质子溶剂是二甲基乙酰胺并且该非水极性质子溶剂是丙二醇。
18.如权利要求1所述的配制品,进一步包括一种药学上可接受的抗氧化剂。
19.如权利要求1所述的配制品,包括约5mg/mL到约200mg/mL的苯达莫司汀或它的药学上可接受的盐。
20.如权利要求1所述的配制品,包括约5mg/mL到约120mg/mL的苯达莫司汀或它的药学上可接受的盐。
21.如权利要求1所述的配制品,包括至少约5mg/mL的苯达莫司汀或它的药学上可接受的盐。
22.权利要求1所述的配制品,包括至少约40mg/mL的苯达莫司汀或它的药学上可接受的盐。
23.如权利要求1所述的配制品,包括至少约60mg/mL的苯达莫司汀或它的药学上可接受的盐。
24.如权利要求1所述的配制品,包括至少约80mg/mL的苯达莫司汀或它的药学上可接受的盐。
25.如权利要求1所述的配制品,包括至少约100mg/mL的苯达莫司汀或它的药学上可接受的盐。
26.如权利要求1所述的配制品,包括至少约200mg/mL的苯达莫司汀或它的药学上可接受的盐。
27.如权利要求1所述的配制品,其中该配制品在约5℃下持续约30天到约365天是稳定的。
28.权利要求1所述的配制品,其中该配制品在约5℃下持续至少约30天是稳定的。
29.如权利要求1所述的配制品,其中该配制品在5℃下持续至少约90天是稳定的。
30.如权利要求1所述的配制品,其中该配制品在约5℃下持续至少约180天是稳定的。
31.如权利要求1所述的配制品,其中对该配制品的分析显示该配制品含有不少于暴露在储存条件之前所存在的苯达莫司汀的量的约90%。
32.如权利要求1所述的配制品,其中该对配制品的分析显示该配制品含有不少于暴露在储存条件之前所存在的苯达莫司汀的量的约95%。
33.如权利要求31和32中任一项所述的配制品,其中所述储存条件是在约5℃下持续约30天到约365天。
34.如权利要求31和32中任何一项所述的配制品,其中所述储存条件是在约5℃下持续至少约30天。
35.如权利要求31和32中任何一项所述的配制品,其中这些储存条件是在约5℃下持续至少约90天。
36.权利要求31和32中任何一项所述的配制品,其中储存条件是在约5℃条件下持续至少约180天。
37.如权利要求1和4中任何一项所述的配制品,进一步包括至少一种药学上可接受的赋形剂。
38.如权利要求1和4中任何一项所述的配制品,进一步包括一种抗氧化剂、一种表面活性剂、一种类脂、一种填充剂、一种有机酸、一种亲水性聚合物、一种络合剂、一种防腐剂或它们的一种组合。
39.如权利要求1和4中任何一项所述的配制品,进一步包括至少一种抗肿瘤药。
40.如权利要求4所述的配制品,其中该配制品包括10摩尔/升或更少的非水极性质子溶剂。
41.如权利要求4所述的配制品,其中该配制品包括约4到约9.5摩尔/升之间的非水极性质子溶剂。
42.如权利要求4所述的配制品,其中该配制品包括约9.1摩尔/升的非水极性质子溶剂。
43.如权利要求4所述的配制品,其中该配制品包括约4.6摩尔/升的非水极性质子溶剂。
44.如权利要求4所述的配制品,其中该配制品包括按该配制品的体积计90%或更少的非水极性质子溶剂。
45.如权利要求1和4中任何一项所述的配制品,包括约0.4%或更少的HP1。
46.如权利要求1和4中任何一项所述的配制品,包括约0.1%或更少的HP1。
47.如权利要求1和4中任何一项所述的配制品,包括约1.5%或更少的DCE。
48.如权利要求1和4中任何一项所述的配制品,包括约0.7%或更少的BM1二聚物。
49.如权利要求17所述的配制品,包括约1.5%或更少的PG-1、PG-2或它们的一种组合。
50.一种制备苯达莫司汀或它的一种药学上可接受的盐的注射配制品的方法,包括:
提供一种液体药物配制品,该液体药物配制品包括苯达莫司汀,或它的一种药学上可接受的盐,以及一种非水溶剂;
用一种药学上可接受的注射稀释剂稀释该液体药物配制品。
51.如权利要求50所述的方法,其中该非水溶剂是一种极性非质子溶剂。
52.如权利要求51所述的方法,其中该极性非质子溶剂是1-甲基-2-吡咯烷酮、1,3-二甲基-2-咪唑啉酮、二甲基乙酰胺、二甲亚砜、丙酮、四氢呋喃、1,4-二氧六环、乙腈、二甲基甲酰胺、碳酸丙烯酯或它们的一种混合物。
53.如权利要求50所述的方法,其中该液体药物配制品进一步包括一种非水极性质子溶剂。
54.如权利要求53所述的方法,其中该非水极性质子溶剂是一种醇、一种聚亚烷基二醇、一种伯酰胺或它们的一种混合物。
55.如权利要求50所述的方法,其中该药学上可接受的注射稀释剂是氯化钠注射液。
56.一种治疗癌症的方法,包括
识别需要癌症治疗的患者;
提供一种液体药物配制品,该液体药物配制品包括一个治疗有效量的苯达莫司汀,或它的一种药学上可接受的盐,以及一种非水溶剂;
用一种药学上可接受的注射稀释剂稀释该液体药物配制品以形成一种药用制剂;
将该药用制剂给予需要治疗的患者。
57.如权利要求56所述的方法,其中该癌症是慢性淋巴细胞白血病、何杰金氏病、非何杰金氏淋巴瘤、多发性骨髓瘤或乳癌。
58.如权利要求56所述的方法,其中该非水溶剂是一种极性非质子溶剂。
59.如权利要求58所述的方法,其中该极性非质子溶剂是1-甲基-2-吡咯烷酮、1,3-二甲基-2-咪唑啉酮、二甲基乙酰胺、二甲亚砜、丙酮、四氢呋喃、1,4-二氧六环、乙腈、二甲基甲酰胺、碳酸丙烯酯或它们的一种混合物。
60.如权利要求56所述的方法,其中该液体药物配制品进一步包括一种非水极性质子溶剂。
61.如权利要求60所述的方法,其中该非水极性质子溶剂是一种醇、一种聚亚烷基二醇、一种伯酰胺或它们的一种混合物。
62.如权利要求56所述的方法,其中该药学上可接受的注射稀释剂是氯化钠注射液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10007408P | 2008-09-25 | 2008-09-25 | |
US61/100,074 | 2008-09-25 | ||
PCT/US2009/058023 WO2010036702A1 (en) | 2008-09-25 | 2009-09-23 | Liquid formulations of bendamustine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410449785.0A Division CN104224703A (zh) | 2008-09-25 | 2009-09-23 | 苯达莫司汀的液体配制品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102164579A true CN102164579A (zh) | 2011-08-24 |
CN102164579B CN102164579B (zh) | 2014-10-15 |
Family
ID=41559533
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410449785.0A Pending CN104224703A (zh) | 2008-09-25 | 2009-09-23 | 苯达莫司汀的液体配制品 |
CN200980137977.5A Active CN102164579B (zh) | 2008-09-25 | 2009-09-23 | 苯达莫司汀的液体配制品 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410449785.0A Pending CN104224703A (zh) | 2008-09-25 | 2009-09-23 | 苯达莫司汀的液体配制品 |
Country Status (9)
Country | Link |
---|---|
US (10) | US20110190363A1 (zh) |
EP (2) | EP2326306A1 (zh) |
JP (1) | JP5670335B2 (zh) |
CN (2) | CN104224703A (zh) |
AU (5) | AU2009296734B2 (zh) |
CA (1) | CA2735899A1 (zh) |
HK (1) | HK1211462A1 (zh) |
MX (1) | MX2011002936A (zh) |
WO (1) | WO2010036702A1 (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103351347A (zh) * | 2013-07-29 | 2013-10-16 | 东南大学 | 盐酸苯达莫司汀杂质dce的制备方法 |
CN104271135A (zh) * | 2012-03-20 | 2015-01-07 | 鹰制药股份有限公司 | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 |
CN104394848A (zh) * | 2012-06-27 | 2015-03-04 | Xeris药物公司 | 小分子药物的用于胃肠外注射的稳定制剂 |
CN105726472A (zh) * | 2016-03-25 | 2016-07-06 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
US9572796B2 (en) | 2010-01-28 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572887B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9642894B2 (en) | 2013-02-06 | 2017-05-09 | Xeris Pharmaceuticals, Inc. | Compositions for rapidly treating severe hypoglycemia |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
CN111201019A (zh) * | 2017-10-05 | 2020-05-26 | 图贝药物有限公司 | 口服苯达莫司汀制剂 |
US10987399B2 (en) | 2011-03-10 | 2021-04-27 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
US11020403B2 (en) | 2017-06-02 | 2021-06-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
US11129940B2 (en) | 2014-08-06 | 2021-09-28 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099724A2 (en) * | 2004-04-13 | 2005-10-27 | Parallel Solutions, Inc. | Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents |
US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
US8858978B2 (en) | 2004-09-28 | 2014-10-14 | Atrium Medical Corporation | Heat cured gel and method of making |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
US20070086958A1 (en) * | 2005-10-14 | 2007-04-19 | Medafor, Incorporated | Formation of medically useful gels comprising microporous particles and methods of use |
US9290777B2 (en) * | 2007-02-05 | 2016-03-22 | National University Of Singapore | Putative cytokinin receptor and methods for use thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
JP5670335B2 (ja) | 2008-09-25 | 2015-02-18 | セファロン、インク. | ベンダムスチン液体製剤 |
KR101355695B1 (ko) * | 2009-02-06 | 2014-01-27 | 더 프록터 앤드 갬블 캄파니 | 붕괴성 수분-함유 캡슐 |
CN102458112A (zh) * | 2009-04-10 | 2012-05-16 | 阿布拉科斯生物科学有限公司 | 纳米颗粒制剂及其用途 |
WO2010129545A2 (en) | 2009-05-04 | 2010-11-11 | Psivida Us, Inc. | Porous silicon drug-eluting particles |
WO2010144675A1 (en) | 2009-06-10 | 2010-12-16 | Plus Chemicals Sa | Polymorphs of bendamustine hcl and processes for preparation thereof |
US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
US11000711B2 (en) * | 2009-12-29 | 2021-05-11 | W. R. Grace & Co.-Conn. | Compositions for forming films having a desired degree of obscuration and methods of making and using the same |
US10729625B2 (en) * | 2010-02-04 | 2020-08-04 | Isp Investments Llc | Self adapting polymers for anhydrous sunscreen formulations |
BR122019005253A8 (pt) * | 2010-02-18 | 2022-07-05 | Athenix Corp | Molécula de ácido nucleico recombinante, vetor, célula hospedeira, polipeptídeo recombinante com atividade pesticida, composição, bem como métodos para o controle de uma população de pragas para matar uma praga, para a produção de um polipeptídeo com atividade pesticida, para a proteção de uma planta de uma praga, e para aumentar o rendimento em uma planta |
WO2011103150A2 (en) * | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
WO2011103247A2 (en) * | 2010-02-18 | 2011-08-25 | Athenix Corp. | Axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, and axmi231 delta-endotoxin genes and methods for their use |
MX2012010479A (es) | 2010-03-08 | 2012-10-09 | Monsanto Technology Llc | Moleculas polinucleotidicas para regulacion genetica en plantas. |
FR2958155B1 (fr) * | 2010-04-02 | 2012-04-20 | Oreal | Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras |
WO2011137563A1 (en) | 2010-05-07 | 2011-11-10 | Unilever Plc | High solvent content emulsions |
AU2011261580B2 (en) * | 2010-06-04 | 2013-12-19 | Monsanto Technology Llc | Transgenic brassica event MON 88302 and methods of use thereof |
WO2011160170A1 (en) * | 2010-06-21 | 2011-12-29 | Peter Maccallum Cancer Institute | Stimulating immune response |
US10322213B2 (en) | 2010-07-16 | 2019-06-18 | Atrium Medical Corporation | Compositions and methods for altering the rate of hydrolysis of cured oil-based materials |
US8383663B2 (en) * | 2010-07-19 | 2013-02-26 | Supratek Pharma Inc. | Bendamustine anionic-catioinic cyclopolysaccharide compositions |
WO2012024176A2 (en) * | 2010-08-19 | 2012-02-23 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis gene with lepidopteran activity |
EP2632463B1 (en) * | 2010-10-28 | 2018-04-04 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for their transdermal delivery |
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
TWI615150B (zh) | 2010-11-01 | 2018-02-21 | 匹史維迪亞美利堅公司 | 用於傳遞治療劑之生物可分解之以矽為主的裝置 |
US20120311734A1 (en) * | 2011-06-04 | 2012-12-06 | The Texas A&M University System | Potato transformation compositions, systems, methods, microorganisms, and plants |
JP2013032332A (ja) * | 2011-07-01 | 2013-02-14 | Lintec Corp | 免疫賦活剤 |
AU2012296987A1 (en) * | 2011-08-12 | 2014-02-27 | Bayer Cropscience Nv | Guard cell-specific expression of transgenes in cotton |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
WO2013040057A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
UA116090C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
US9416363B2 (en) | 2011-09-13 | 2016-08-16 | Monsanto Technology Llc | Methods and compositions for weed control |
PL2755467T3 (pl) | 2011-09-13 | 2018-01-31 | Monsanto Technology Llc | Sposoby i kompozycje do kontroli chwastów |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
ES2911427T3 (es) * | 2011-09-18 | 2022-05-19 | Euro Celtique Sa | Composición farmacéutica que comprende un inhibidor HDAC y un ciclopolisacárido |
CN104011029B (zh) | 2011-09-26 | 2016-06-08 | 费森尤斯卡比肿瘤学有限公司 | 一种制备盐酸苯达莫司汀的改进方法 |
WO2013052114A1 (en) * | 2011-10-05 | 2013-04-11 | Fmc Corporation | Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses |
US9492363B1 (en) * | 2012-01-16 | 2016-11-15 | American Spraytech, L.L.C. | Aerosol sprayable color composition |
US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
CA2861324A1 (en) * | 2012-01-27 | 2013-08-01 | Agile Therapeutics, Inc. | Transdermal hormone delivery |
AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
US20130210879A1 (en) * | 2012-02-14 | 2013-08-15 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
WO2013148919A1 (en) | 2012-03-30 | 2013-10-03 | The Regents Of The University Of Colorado, A Body Corporate | Treatment of multiple myeloma |
US10240161B2 (en) | 2012-05-24 | 2019-03-26 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
JP6338064B2 (ja) * | 2012-08-03 | 2018-06-06 | エムエスエム イノベーションズ、インク. | 腸の前処理のための方法及びキット |
CN113528634A (zh) | 2012-08-14 | 2021-10-22 | 10X基因组学有限公司 | 微胶囊组合物及方法 |
US11591637B2 (en) | 2012-08-14 | 2023-02-28 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10273541B2 (en) | 2012-08-14 | 2019-04-30 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9701998B2 (en) | 2012-12-14 | 2017-07-11 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10221442B2 (en) | 2012-08-14 | 2019-03-05 | 10X Genomics, Inc. | Compositions and methods for sample processing |
US10752949B2 (en) | 2012-08-14 | 2020-08-25 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9951386B2 (en) | 2014-06-26 | 2018-04-24 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10323279B2 (en) | 2012-08-14 | 2019-06-18 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10400280B2 (en) | 2012-08-14 | 2019-09-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9801859B2 (en) | 2012-09-18 | 2017-10-31 | Innopharma Licensing, Llc | Bendamustine formulations |
US9617297B2 (en) * | 2012-10-11 | 2017-04-11 | The Regents Of The University Of California | Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves |
CA2888264A1 (en) | 2012-10-18 | 2014-04-24 | Monsanto Technology Llc | Methods and compositions for plant pest control |
AU2013342015B2 (en) | 2012-11-12 | 2016-11-24 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
DK2732811T3 (en) * | 2012-11-19 | 2016-03-21 | Oncotec Pharma Produktion Gmbh | A process for preparing a freeze-dried composition |
EP3567116A1 (en) | 2012-12-14 | 2019-11-13 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10533221B2 (en) | 2012-12-14 | 2020-01-14 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US9206436B2 (en) * | 2012-12-20 | 2015-12-08 | Ut-Battelle, Llc | Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
AU2013371825B2 (en) | 2013-01-01 | 2019-10-24 | A.B. Seeds Ltd. | Methods of introducing dsRNA to plant seeds for modulating gene expression |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
CA2900543C (en) | 2013-02-08 | 2023-01-31 | 10X Genomics, Inc. | Partitioning and processing of analytes and other species |
US8961680B2 (en) * | 2013-03-08 | 2015-02-24 | Tbf Environmental Technology Inc. | Solvent formulations |
US20140271764A1 (en) * | 2013-03-12 | 2014-09-18 | Psivida Us, Inc. | Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents |
UA123082C2 (uk) | 2013-03-13 | 2021-02-17 | Монсанто Текнолоджи Ллс | Спосіб та гербіцидна композиція для боротьби з видами рослин роду sorghum |
AR095233A1 (es) | 2013-03-13 | 2015-09-30 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
AU2014240095A1 (en) * | 2013-03-15 | 2015-10-08 | Maria Beug-Deeb Inc. Dba T&M Associates | Methods and compositions for cleaning and disinfecting surfaces |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
JP2016512839A (ja) | 2013-03-15 | 2016-05-09 | シヴィダ・ユーエス・インコーポレイテッドPsivida Us, Inc. | 治療物質の送達のための生体内分解性ケイ素系組成物 |
CA2817728A1 (en) * | 2013-05-31 | 2014-11-30 | Pharmascience Inc. | Abuse deterrent immediate release formulation |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
CA2918387C (en) | 2013-07-19 | 2021-11-02 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
MX2016002502A (es) * | 2013-08-27 | 2017-02-28 | Voudouris Vasilios | Composiciones farmaceuticas de bendamustina. |
LT3421033T (lt) * | 2013-10-07 | 2022-11-10 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Atazanaviro ir kobicistato kompozicija, skirta živ gydymui |
US20160235717A1 (en) * | 2013-10-11 | 2016-08-18 | Luitpold Pharmaceuticals, Inc. | Bendamustine pharmaceutical compositions |
NZ719544A (en) | 2013-11-04 | 2022-09-30 | Beeologics Inc | Compositions and methods for controlling arthropod parasite and pest infestations |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
IN2014CH00151A (zh) * | 2014-01-13 | 2015-07-17 | Hetero Research Foundation | |
WO2015108982A2 (en) | 2014-01-15 | 2015-07-23 | Monsanto Technology Llc | Methods and compositions for weed control using epsps polynucleotides |
EP3116481A1 (en) * | 2014-03-13 | 2017-01-18 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
CN106413896B (zh) | 2014-04-10 | 2019-07-05 | 10X基因组学有限公司 | 用于封装和分割试剂的流体装置、系统和方法及其应用 |
GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
CN106795515B (zh) | 2014-06-23 | 2021-06-08 | 孟山都技术公司 | 用于经由rna干扰调控基因表达的组合物和方法 |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
EP3161160B1 (en) | 2014-06-26 | 2021-10-13 | 10X Genomics, Inc. | Methods of analyzing nucleic acids from individual cells or cell populations |
AU2015287920A1 (en) | 2014-07-08 | 2017-01-19 | Mimedx Group, Inc. | Micronized wharton's jelly |
US20160022604A1 (en) * | 2014-07-23 | 2016-01-28 | Cadila Healthcare Limited | Directly compressed ospemifene compositions |
WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
JP2017528458A (ja) * | 2014-09-11 | 2017-09-28 | ゲリタ アクチェンゲゼルシャフト | ゼラチン/ペクチン粒子 |
CA2961639A1 (en) | 2014-09-17 | 2016-03-24 | Lonza, Inc. | Activated disinfectant hydrogen peroxide compositions |
CN114807307A (zh) | 2014-10-29 | 2022-07-29 | 10X 基因组学有限公司 | 用于靶核酸测序的方法和组合物 |
US9975122B2 (en) | 2014-11-05 | 2018-05-22 | 10X Genomics, Inc. | Instrument systems for integrated sample processing |
US9603930B2 (en) * | 2014-12-04 | 2017-03-28 | Navinta, Llc | Liquid bendamustine formulation |
EA201791542A1 (ru) * | 2015-01-06 | 2018-03-30 | Осаму Ямада | Лекарственный препарат, устройство для лечения заболеваний крови, косметическое средство, продукт питания и напиток, использующий вещество, полученное методом синтеза в процессе горения |
SG11201705615UA (en) | 2015-01-12 | 2017-08-30 | 10X Genomics Inc | Processes and systems for preparing nucleic acid sequencing libraries and libraries prepared using same |
US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
EP3262407B1 (en) | 2015-02-24 | 2023-08-30 | 10X Genomics, Inc. | Partition processing methods and systems |
JP2018505688A (ja) | 2015-02-24 | 2018-03-01 | 10エックス ゲノミクス,インコーポレイテッド | 標的化核酸配列包括度(coverage)のための方法 |
CA2977961A1 (en) | 2015-02-25 | 2016-09-01 | The Procter & Gamble Company | Fibrous structures comprising a surface softening composition |
US20160303043A1 (en) * | 2015-04-16 | 2016-10-20 | Kate Somerville Skincare, LLC | Self-foaming compositions and methods |
UY36703A (es) | 2015-06-02 | 2016-12-30 | Monsanto Technology Llc | Composiciones y métodos para la administración de un polinucleótido en una planta |
AU2016270913A1 (en) | 2015-06-03 | 2018-01-04 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
WO2017011249A1 (en) | 2015-07-10 | 2017-01-19 | The Procter & Gamble Company | Fabric care composition comprising metathesized unsaturated polyol esters |
US10774370B2 (en) | 2015-12-04 | 2020-09-15 | 10X Genomics, Inc. | Methods and compositions for nucleic acid analysis |
WO2017197338A1 (en) | 2016-05-13 | 2017-11-16 | 10X Genomics, Inc. | Microfluidic systems and methods of use |
AU2017293856B2 (en) | 2016-07-08 | 2020-04-02 | The Gillette Company Llc | Liquid compositions for hair removal devices comprising metathesized unsaturated polyol esters |
US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
DE102016223333A1 (de) * | 2016-11-24 | 2018-05-24 | Henkel Ag & Co. Kgaa | Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer |
US10815525B2 (en) | 2016-12-22 | 2020-10-27 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10550429B2 (en) | 2016-12-22 | 2020-02-04 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
US10011872B1 (en) | 2016-12-22 | 2018-07-03 | 10X Genomics, Inc. | Methods and systems for processing polynucleotides |
EP4310183A3 (en) | 2017-01-30 | 2024-02-21 | 10X Genomics, Inc. | Methods and systems for droplet-based single cell barcoding |
MA47686A (fr) | 2017-03-01 | 2021-05-12 | Arena Pharm Inc | Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés |
US10398670B2 (en) * | 2017-04-24 | 2019-09-03 | Knoze Jr. Corporation | Oral microbiota promotion for oral and/or sinus infections |
US10844372B2 (en) | 2017-05-26 | 2020-11-24 | 10X Genomics, Inc. | Single cell analysis of transposase accessible chromatin |
SG11201901822QA (en) | 2017-05-26 | 2019-03-28 | 10X Genomics Inc | Single cell analysis of transposase accessible chromatin |
GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
US10471033B2 (en) * | 2017-09-15 | 2019-11-12 | Knoze Jr. Corporation | Oral microbiota promotion for immune system associated inflammations |
SG11201913654QA (en) | 2017-11-15 | 2020-01-30 | 10X Genomics Inc | Functionalized gel beads |
WO2019097413A1 (en) * | 2017-11-15 | 2019-05-23 | Intas Pharmaceuticals Ltd. | Stable non-aqueous pharmaceutical compositions |
US10829815B2 (en) | 2017-11-17 | 2020-11-10 | 10X Genomics, Inc. | Methods and systems for associating physical and genetic properties of biological particles |
KR20200136997A (ko) | 2018-03-29 | 2020-12-08 | 프로젝트 파마슈틱스 게엠베하 | 액체 약학적 제형 |
CN112262218A (zh) | 2018-04-06 | 2021-01-22 | 10X基因组学有限公司 | 用于单细胞处理中的质量控制的系统和方法 |
US20210275500A1 (en) * | 2018-08-17 | 2021-09-09 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
US11730815B2 (en) | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
US11707450B1 (en) | 2022-03-03 | 2023-07-25 | Slayback Pharma Llc | Stable pharmaceutical compositions of bendamustine |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE159289C (zh) | 1903-10-08 | 1905-03-16 | ||
DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
DD159877A1 (de) | 1981-06-12 | 1983-04-13 | Wolfgang Krueger | Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure |
IT1153974B (it) * | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
DE3446873A1 (de) * | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
US5204335A (en) * | 1986-10-31 | 1993-04-20 | Asta Pharma Aktiengesellschaft | Ifosfamide lyophilisate and process for its preparation |
US5162115A (en) * | 1989-05-09 | 1992-11-10 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
DD293808A5 (de) | 1990-04-23 | 1991-09-12 | Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
DK0669836T3 (da) * | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
KR100335549B1 (ko) * | 1993-10-27 | 2002-11-29 | 파마시아 앤드 업존 캄파니 | 안정화된프로스타글란딘e1 |
US5561121A (en) | 1993-11-09 | 1996-10-01 | American Cyanamid Company | Stable lyophilized thiotepa composition |
US5955504A (en) | 1995-03-13 | 1999-09-21 | Loma Linda University Medical Center | Colorectal chemoprotective composition and method of preventing colorectal cancer |
DE19529057B4 (de) * | 1995-08-08 | 2007-12-13 | Baxter Healthcare S.A. | Ifosfamid-Lyophilisat-Zubereitungen |
US6261537B1 (en) * | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US20040072889A1 (en) * | 1997-04-21 | 2004-04-15 | Pharmacia Corporation | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia |
US6034256A (en) * | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
NZ509376A (en) * | 1998-07-09 | 2003-10-31 | Francis A Nardella | Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia |
US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
US6569402B1 (en) * | 1998-12-18 | 2003-05-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
US6380210B1 (en) * | 1999-04-02 | 2002-04-30 | Neurogen Corporation | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors |
US6545034B1 (en) * | 1999-07-23 | 2003-04-08 | The Regents Of The University Of California | Use of etodolac for the treatment of chronic lymphocytic leukemia |
DE10016077A1 (de) | 2000-03-31 | 2001-12-13 | Cellcontrol Biomedical Lab Gmb | Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen |
US20040152672A1 (en) * | 2000-08-09 | 2004-08-05 | Carson Dennis A. | Indole compounds useful for the treatment of cancer |
CN1487936A (zh) * | 2000-12-11 | 2004-04-07 | ����ҩƷ��ҵ��ʽ���� | 具有改进吸收性能的药物组合物 |
WO2002048141A1 (en) * | 2000-12-11 | 2002-06-20 | Takeda Chemical Industries, Ltd. | Medicinal compositions improved in solublity in water |
DE10294792D2 (de) * | 2001-10-15 | 2004-09-16 | Hemoteq Gmbh | Beschichtung von Stents zur Verhinderung von Restenose |
US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
JP4443935B2 (ja) | 2002-03-22 | 2010-03-31 | ルートヴィヒ マクシミリアン ウニヴェルジテート | 高用量細胞傷害性化学療法後の造血回復、好中球減少性発熱、および抗菌処置の予測のための細胞能力試験 |
EP1354952A1 (en) | 2002-04-17 | 2003-10-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Smac-peptides as therapeutics against cancer and autoimmune diseases |
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
NZ536330A (en) | 2002-05-09 | 2007-08-31 | Hemoteq Ag | Medical devices such as stents comprising haemocompatible coating, production and use thereof |
US20040096436A1 (en) * | 2002-08-02 | 2004-05-20 | Regents Of The University Of California | Methods for inhibiting protein kinases in cancer cells |
DE10304403A1 (de) * | 2003-01-28 | 2004-08-05 | Röhm GmbH & Co. KG | Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
TW200427463A (en) * | 2003-02-14 | 2004-12-16 | Salmedix | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
EP1648454A1 (en) * | 2003-07-25 | 2006-04-26 | Wyeth | Cci-779 lyophilized formulations |
US20060128777A1 (en) * | 2004-11-05 | 2006-06-15 | Bendall Heather H | Cancer treatments |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
US7872050B2 (en) * | 2005-03-14 | 2011-01-18 | Yaupon Therapeutics Inc. | Stabilized compositions of volatile alkylating agents and methods of using thereof |
AR072777A1 (es) * | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
JP5670335B2 (ja) | 2008-09-25 | 2015-02-18 | セファロン、インク. | ベンダムスチン液体製剤 |
-
2009
- 2009-09-23 JP JP2011529180A patent/JP5670335B2/ja active Active
- 2009-09-23 AU AU2009296734A patent/AU2009296734B2/en active Active
- 2009-09-23 CN CN201410449785.0A patent/CN104224703A/zh active Pending
- 2009-09-23 MX MX2011002936A patent/MX2011002936A/es active IP Right Grant
- 2009-09-23 CA CA2735899A patent/CA2735899A1/en not_active Abandoned
- 2009-09-23 EP EP09740213A patent/EP2326306A1/en not_active Withdrawn
- 2009-09-23 EP EP15152744.7A patent/EP2889029A1/en not_active Withdrawn
- 2009-09-23 CN CN200980137977.5A patent/CN102164579B/zh active Active
- 2009-09-23 WO PCT/US2009/058023 patent/WO2010036702A1/en active Application Filing
-
2011
- 2011-03-15 US US13/048,325 patent/US20110190363A1/en not_active Abandoned
- 2011-12-01 HK HK15111733.2A patent/HK1211462A1/zh unknown
-
2012
- 2012-01-31 US US13/362,430 patent/US8344006B2/en active Active
- 2012-10-19 US US13/655,498 patent/US20130041004A1/en not_active Abandoned
-
2013
- 2013-11-20 US US14/084,768 patent/US20140080881A1/en not_active Abandoned
-
2014
- 2014-01-09 US US14/151,242 patent/US20140128443A1/en not_active Abandoned
- 2014-03-21 US US14/221,422 patent/US20140206733A1/en not_active Abandoned
-
2015
- 2015-07-31 US US14/814,570 patent/US20150335750A1/en not_active Abandoned
- 2015-07-31 AU AU2015207940A patent/AU2015207940B2/en active Active
-
2016
- 2016-05-18 AU AU2016203246A patent/AU2016203246B2/en active Active
- 2016-10-19 AU AU2016247123A patent/AU2016247123A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,182 patent/US20180125824A1/en not_active Abandoned
-
2018
- 2018-03-23 AU AU2018202107A patent/AU2018202107A1/en not_active Abandoned
-
2020
- 2020-03-31 US US16/835,562 patent/US20210008035A1/en not_active Abandoned
- 2020-09-09 US US17/015,175 patent/US20210113530A1/en not_active Abandoned
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11103483B2 (en) | 2010-01-28 | 2021-08-31 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572796B2 (en) | 2010-01-28 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US11872214B2 (en) | 2010-01-28 | 2024-01-16 | Eagle Pharmaceuticals, Inc. | Formulations of Bendamustine |
US11844783B2 (en) | 2010-01-28 | 2023-12-19 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572797B2 (en) | 2010-01-28 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US10010533B2 (en) | 2010-01-28 | 2018-07-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US10987399B2 (en) | 2011-03-10 | 2021-04-27 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
US9572887B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9572888B2 (en) | 2012-03-20 | 2017-02-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9597397B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9597399B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
US9597398B2 (en) | 2012-03-20 | 2017-03-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
CN104271135A (zh) * | 2012-03-20 | 2015-01-07 | 鹰制药股份有限公司 | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 |
US9579384B2 (en) | 2012-03-20 | 2017-02-28 | Eagle Pharmaceuticals, Inc. | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
CN104271135B (zh) * | 2012-03-20 | 2017-05-17 | 赛多斯有限责任公司 | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 |
US10052385B2 (en) | 2012-03-20 | 2018-08-21 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
CN107913248A (zh) * | 2012-06-27 | 2018-04-17 | Xeris药物公司 | 小分子药物的用于胃肠外注射的稳定制剂 |
CN104394848B (zh) * | 2012-06-27 | 2017-12-01 | Xeris药物公司 | 小分子药物的用于胃肠外注射的稳定制剂 |
CN104394848A (zh) * | 2012-06-27 | 2015-03-04 | Xeris药物公司 | 小分子药物的用于胃肠外注射的稳定制剂 |
US11446310B2 (en) | 2012-06-27 | 2022-09-20 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US10765683B2 (en) | 2012-06-27 | 2020-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
US9642894B2 (en) | 2013-02-06 | 2017-05-09 | Xeris Pharmaceuticals, Inc. | Compositions for rapidly treating severe hypoglycemia |
CN103351347A (zh) * | 2013-07-29 | 2013-10-16 | 东南大学 | 盐酸苯达莫司汀杂质dce的制备方法 |
US11129940B2 (en) | 2014-08-06 | 2021-09-28 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US10485850B2 (en) | 2015-09-25 | 2019-11-26 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
CN105726472B (zh) * | 2016-03-25 | 2019-12-13 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
CN110772480B (zh) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | 苯达莫司汀药剂组合物及应用 |
CN110772480A (zh) * | 2016-03-25 | 2020-02-11 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
CN105726472A (zh) * | 2016-03-25 | 2016-07-06 | 南京康玻斯医药科技有限公司 | 苯达莫司汀药剂组合物及应用 |
US11020403B2 (en) | 2017-06-02 | 2021-06-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
US11833157B2 (en) | 2017-06-02 | 2023-12-05 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
CN111201019A (zh) * | 2017-10-05 | 2020-05-26 | 图贝药物有限公司 | 口服苯达莫司汀制剂 |
CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
Also Published As
Publication number | Publication date |
---|---|
HK1211462A1 (zh) | 2016-05-27 |
US20140080881A1 (en) | 2014-03-20 |
AU2016203246A1 (en) | 2016-06-09 |
US20140206733A1 (en) | 2014-07-24 |
JP2012503666A (ja) | 2012-02-09 |
AU2016247123A1 (en) | 2016-11-03 |
EP2889029A1 (en) | 2015-07-01 |
US8344006B2 (en) | 2013-01-01 |
US20150335750A1 (en) | 2015-11-26 |
US20210113530A1 (en) | 2021-04-22 |
AU2016203246B2 (en) | 2017-09-21 |
CN104224703A (zh) | 2014-12-24 |
AU2009296734B2 (en) | 2016-02-18 |
US20120129904A1 (en) | 2012-05-24 |
AU2015207940B2 (en) | 2016-11-10 |
US20210008035A1 (en) | 2021-01-14 |
US20140128443A1 (en) | 2014-05-08 |
US20110190363A1 (en) | 2011-08-04 |
CA2735899A1 (en) | 2010-04-01 |
US20130041004A1 (en) | 2013-02-14 |
AU2015207940A1 (en) | 2015-08-20 |
AU2018202107A1 (en) | 2018-04-19 |
EP2326306A1 (en) | 2011-06-01 |
US20180125824A1 (en) | 2018-05-10 |
CN102164579B (zh) | 2014-10-15 |
AU2009296734A1 (en) | 2010-04-01 |
JP5670335B2 (ja) | 2015-02-18 |
WO2010036702A1 (en) | 2010-04-01 |
MX2011002936A (es) | 2011-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102164579B (zh) | 苯达莫司汀的液体配制品 | |
US9572888B2 (en) | Formulations of bendamustine | |
US20160213682A1 (en) | Fulvestrant compositions | |
KOc et al. | Pharmacokinetic disposition of enrofloxacin in brown trout (Salmo trutta fario) after oral and intravenous administrations | |
US11903934B2 (en) | Rifabutin treatment methods, uses, and compositions | |
KR20130035514A (ko) | 난용성 약물의 가용화를 위한 조성물 | |
CN106619541A (zh) | 艾沙康唑鎓硫酸盐冻干粉针剂及制备方法 | |
US20150087681A1 (en) | Bendamustine HCL Stable Lyophilized Formulations | |
EP3010483A1 (en) | Lyophilized formulations of bendamustine hydrochloride | |
KR20220103697A (ko) | 리파부틴 치료법, 용도 및 조성물 | |
BR102019004382A2 (pt) | Composição estéril injetável | |
WO2016079749A2 (en) | Process for preparation of parenteral formulation of anidulafungin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: Pennsylvania, America Patentee after: Safran Co.,Ltd. Address before: Pennsylvania, America Patentee before: CEPHALON, Inc. |
|
CP01 | Change in the name or title of a patent holder |